YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$15.39 USD
+0.22 (1.45%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $15.41 +0.02 (0.13%) 7:32 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Y-mAbs Therapeutics, Inc. [YMAB]
Reports for Purchase
Showing records 21 - 40 ( 153 total )
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Chinese Office of Cybersecurity Review Investigating Micron
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DANYELZA Sales Beat Consensus; 3Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to Neutral; A Swing and a Miss for Omburtamab
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FDA Advisory Committee Votes Against Omburtamab; Lowering PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal OMBLASTYS Results Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
YMAB?s Data is a Treat for the Upcoming FDA AdCom
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ESMO 2022 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D